The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Lenvatinib in Thyroid Cancer With and Without VEGF-Targeted Therapy

Matthew H. Taylor, MD
Published Online: 12:03 AM, Tue June 2, 2015


Matthew H. Taylor, MD, Oregon Health and Science University, discusses the efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.